The Lundquist Institute out-licenses development of a synthetic lung surfactant formulation

-AGREEMENT ADVANCES EVOLUTION OF SYNTHETIC LUNG SURFACTANTS TO TREAT RESPIRATORY DISTRESS SYNDROME IN PREMATURE INFANTS IN LOW- AND MIDDLE-INCOME COUNTRIES- LOS ANGELES (March 8, 2021) — The Lundquist Institute (TLI) and The Bill & Melinda Gates Medical Research Institute (Gates MRI) executed a license agreement for TLI intellectual property covering a synthetic lung surfactant formulation…

Details

Carolina clinical trial tests effectiveness of mouthwash to kill coronavirus

CHAPEL HILL, N.C. — Researchers at the University of North Carolina at Chapel Hill Adams School of Dentistry have launched a clinical trial to test whether mouthwash can reduce a person’s risk of spreading coronavirus. Laboratory experiments have shown mouthwash can quickly kill coronaviruses, but there’s no evidence mouthwash can prevent the virus from infecting…

Details

Research foresees an end to deregulated competitive public transport

Research from the University of Kent predicts an end to deregulated competitive pubic transport in the UK as a consequence of Covid-19 social distancing measures leading to drastically reduced ridership, requiring a major rethinking of the provision of public transport. This paper, published in Transport Policy, argues that the situation will require a fundamental approach…

Details

Tocilizumab cuts mortality risk in severely ill COVID-19 patients finds new trial conducted in India

Tocilizumab, an anti-inflammatory drug used to treat rheumatoid arthritis, improves outcomes in severely ill COVID-19 patients, finds the results of a new trial conducted in hospitals across India — one of the world’s most ethnically diverse countries. Researchers from the University of Bristol and Medanta Institute of Education and Research in India who led the…

Details